Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Syntex was a pioneering pharmaceutical company that played a pivotal role in the development of the first oral contraceptive pill. Originally founded in Mexico City before relocating its headquarters to Palo Alto, California, the company became a global leader in steroid chemistry and hormone-based therapies. Syntex is also widely recognized for developing the blockbuster nonsteroidal anti-inflammatory drug (NSAID) naproxen, marketed under the brand names Naprosyn and Aleve. The company's research environment in Silicon Valley helped foster the region's burgeoning biotechnology industry and produced several notable spin-offs. In 1994, Syntex was acquired by Roche for $5.3 billion, and its operations were subsequently integrated into the Roche Group.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Syntex Laboratories.